The Zacks Analyst Blog Highlights: Bristol-Myers Squibb, Amylin Pharmaceuticals, Eli Lilly, AstraZeneca and Monster Worldwide

News provided by

Jul 03, 2012, 09:30 ET

CHICAGO, July 3, 2012 /PRNewswire/ -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Bristol-Myers Squibb Company (NYSE:BMY), Amylin Pharmaceuticals, Inc. (Nasdaq:AMLN), Eli Lilly & Company (NYSE:LLY), AstraZeneca (NYSE:AZN) and Monster Worldwide, Inc. (NYSE:MWW).

(Logo: http://photos.prnewswire.com/prnh/20101027/ZIRLOGO)

Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=5513

Here are highlights from Monday's Analyst Blog:

Bristol-Myers to Buy Amylin

In a bid to diversify its business to combat the generic threat and bolster its position in the lucrative diabetes market, Bristol-Myers Squibb Company (NYSE:BMY) recently announced that it will purchase biopharmaceutical company Amylin Pharmaceuticals, Inc. (Nasdaq:AMLN) for $31.00 per share or approximately $5.3 billion in cash.

Moreover, the deal will see Bristol-Myers assuming Amylin's net debt and making a contractual payment to Amylin's former partner, Eli Lilly & Company (NYSE:LLY). The total value of the deal will extend to $7 billion in that case. We remind investors that in November 2011, Amylin and Eli Lilly terminated their partnership for the worldwide development and commercialization of exenatide.

Bristol-Myers also announced that it will expand its partnership with AstraZeneca (NYSE:AZN) on diabetes drugs for developing and marketing Amylin's diabetes candidates/drugs following the closure of the Amylin deal. The expanded deal will see AstraZeneca making a payment of $3.4 billion in cash to Bristol-Myers.

This cash inflow will bolster Bristol-Myers' balance sheet since the Amylin buy means it will shell out a significant amount. Bristol-Myers and AstraZeneca will share the profits and losses from the partnership equally.

Offer Price Represents Significant Premium

The offer price represents a premium of 10% on Amylin's closing price as of July 29, 2012. The Boards of both companies have approved the deal, which will close following a cash tender offer and second step merger. Amylin's stockholders have been advised by the company's board to tender their shares when Bristol-Myers launches the cash tender offer.

Deal is Mutually Beneficial

We believe that Bristol-Myers' impending takeover of Amylin will benefit both companies. We note that following the termination of Amylin's exenatide agreement with Eli Lilly in November 2011, Amylin has been considered to be a potential takeover candidate for companies with a focus on diabetes. Amylin's exenatide franchise consists of Byetta and Bydureon (once-weekly exenatide).

While Byetta sales have been lagging expectations, Bydureon, which was launched earlier this year in the US, could very well be a blockbuster. Moreover, the deal is beneficial for Amylin's stockholders as can be seen from the significant premium on the offer price. Amylin's shares shot up significantly from the time acquisition rumors started in March 2012.

The Amylin acquisition is a smart, strategic move by Bristol-Myers since it already has a presence in the diabetes market (Onglyza and Kombiglyze). Moreover, the loss of exclusivity of its blockbuster blood-thinner Plavix on May 17, 2012 in the US is likely to result in substantial revenue losses for Bristol-Myers.

The Amylin buy, through which Bristol-Myers aims to expand its presence in the lucrative diabetes market, is an effort to combat the substantial revenue losses due to Plavix's genericization in the US.

The announcement of the Amylin deal is the second major deal for Bristol-Myers this year. In February 2012, Bristol-Myers purchased Inhibitex, Inc., for $2.5 billion targeting the lucrative HCV market.

Neutral on Bristol-Myers, Amylin

We currently have a Neutral recommendation on Bristol-Myers. The stock carries a Zacks #3 Rank (Hold rating) in the short run. Our stance is similar on Amylin.

Monster's 6Sense Gains Traction

The 6Sense semantic search technology from Monster, the flagship brand of Monster Worldwide, Inc. (NYSE:MWW) is helping companies successfully find the right candidate for the right job in a quick and cost effective manner.

As competition for jobs get intense and unemployment remains high, the number of vacancies continue to increase with an average of 3.26 million positions waiting to be filled in the U.S.

Monster's 6 Sense Technology enables recruiters to source quality job candidates and fill jobs in a faster manner.

Monster's patented 6Sense semantic search and matching technology act as a backbone for most of the products, which in turn, facilitates both the job seekers and employers.

Monster continues to make investments in the technology platform that allows the company to launch innovative products and services on a global basis.

Monster acquired Trovix Inc. in 2008 and this new technology is based on the technology from Trovix. Trovix provides career-related products and services that use advanced search technology, while focusing on key attributes, such as skills, work history and education.

The 6Sense technology basically transforms traditional keyword-based processes and aids customers by matching candidates to their required job specifications.

Want more from Zacks Equity Research? Subscribe to the free Profit from the Pros newsletter: http://at.zacks.com/?id=5515.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today: http://at.zacks.com/?id=5517

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leon Zacks. As a PhD from MIT Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at http://at.zacks.com/?id=5518.

Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.

Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts

Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.

Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
[email protected]
http://www.zacks.com

SOURCE Zacks Investment Research, Inc.